Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBiopharma Cred. Share News (BPCR)

Share Price Information for Biopharma Cred. (BPCR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.834
Bid: 0.834
Ask: 0.84
Change: -0.002 (-0.24%)
Spread: 0.006 (0.719%)
Open: 0.838
High: 0.838
Low: 0.834
Prev. Close: 0.836
BPCR Live PriceLast checked at -
BioPharma Credit is an Investment Trust

To generate long-term shareholder returns, predominantly in the form of sustainable income distributions from exposure to the life sciences industry.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EARNINGS UPDATES: MP Evans dividend outlook bright; ScS share buyback

Tue, 22nd Mar 2022 21:01

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

----------

Sabre Insurance Group PLC - Surrey, England-based motor insurance underwriter - Gross written premium in 2021 falls to GBP169.3 million from GBP173.2 million in 2020 and pretax profit declines to GBP37.2 million from GBP49.1 million. Says it maintained disciplined approach to pricing throughout the year, with rate increases in-line with, or ahead of, expected claims costs. "After several years of gritting our teeth and sticking rigorously to our 'profitability over volume' strategy, our discipline is paying off, we have turned the page as we enter 2022, and are now entering a far more exciting chapter," says Chief Executive Geoff Carter. Says it has seen seen positive premium momentum coming into 2022 and has been able to apply "significant" price increases. "We would therefore anticipate significant year-on-year gross written premium growth whilst continuing to deliver a COR towards the upper end of our target COR range," firm says. Dividend for 2021 falls to 13.0p from 16.0p in 2020.

----------

MP Evans Group PLC - producer of palm oil in Indonesia - Revenue for 2021 rises to USD276.6 million from USD174.5 million in 2020, while pretax profit jumps to USD112.5 million from USD28.4 million. "2021 has been an excellent year for the group. Crop and production have risen further in line with our long-term strategic plans, whilst the palm-oil market has gone from strength to strength," says Executive Chair Peter Hadsley-Chaplin. Recommends final dividend of 25p, taking total ordinary payout for year to 35p and, in addition, firm paid a dividend 5p dividend in February. "The board intends, wherever possible, to continue the group's long-term trend of increasing dividends, which have accelerated in recent years. The board believes that the projected increases in both crop and production form a sound basis for further dividend increases," it says.

----------

ScS Group PLC - Sunderland-based retailer of furniture and flooring - Revenue for half-year to January 29 declines 16% to GBP145.9 million from GBP173.9 million, with result slightly behind the GBP152.0 million generated two years ago in a pre-pandemic period. Firm swings to pretax loss of GBP3.6 million in the half from profit of GBP17.7 million year-on-year. "During the period increased lead times for product due to supply chain disruption impacted delivered gross sales, revenue and profitability but has enabled the group to build a strong order book. This supports the group's expectation of delivering profitable full year results in line with market expectations," firm says. Raises interim dividend by 50% to 4.5 and declares share buyback of up to GBP7 million.

----------

Yu Group PLC - Nottingham, England-based energy supplier - Revenue for 2021 grows to GBP155.4 million from GBP101.5 million in 2020, and swings to pretax profit of GBP3.4 million from loss of GBP1.5 million. "2021 was a remarkable year and a stellar performance that's seen the group outperform forecasts in terms of profitability, growth and forward looking contracted revenue," says Chief Executive Bobby Kalar. Looking out, firm has "significant confidence" in high revenue growth based on increased forward contract book. "Despite turbulence in the wider external market, we remain strong and focussed on delivering continued profitable and controlled growth," firm adds.

----------

YouGov PLC - London-based research and data analytics company - Revenue for six months to the end of January GBP101.2 million, up 28% on GBP79.0 million a year before. Pretax profit rises 18% to GBP9.2 million from GBP7.8 million. Data Products revenue increases by 31%, Data Services revenue up by 9% and Custom Research revenue up by 39%. "YouGov delivered a record performance in the first half of the current financial year. In addition to accelerated and broad-based growth, we achieved sustained profitability and strong cash generation as we continued to focus on driving long-term shareholder value in line with our strategy," says Chief Executive Stephan Shakespeare. Firm adds that second half has started well and current trading remains slightly ahead of board expectations for full-year.

----------

Accesso Technology Group PLC - Berkshire, England-based provider of software for leisure, entertainment and cultural sectors - Says 2021 performance was "simply outstanding" as revenue jumps to USD124.8 million from USD56.1 million in 2020, and swings to pretax profit of USD12.1 million from loss of USD32.9 million. "We delivered record revenue and record profit during another challenging year in our end markets as they continued to recover at varying levels through the year," says Chief Executive Steve Brown. Says 2022 has started strongly with trading volumes in January and February encouraging. Is "cautiously optimistic" on another year of good progress, though does warn that cost base expected to increase as it returns to normal staffing levels.

----------

Kape Technologies PLC - Isle of Man-based digital security and privacy software provider - Revenue for 2021 exceeds management forecasts, rising 89% to USD230.7 million from USD122.2 million in 2020. Pretax profit jumps to USD32.6 million from USD7.3 million. "In 2021, we achieved record customer growth, providing further evidence that our products remain both compelling and highly innovative, and, more importantly, our customers continue to utilise our services for many years," says Chief Executive Ido Erlichman. Says firm has continued this momentum into 2022 and is positive on prospects. Is confident of achieving forecasts announced at time of ExpressVPN acquisition of 2022 revenue of between USD610 million and USD 624 million and pro forma adjusted earnings before interest, tax, depreciation and amortisation of between USD166 million and USD172 million. "The significant progress that was delivered during 2021 has provided Kape with the solid foundations to further extend our reach across the digital privacy and security market in 2022 and beyond," company says.

----------

Real Estate Investors PLC - Midlands, UK-focused real estate investment trust - Revenue for 2021 dips to GBP16.0 million from GBP16.4 million, though firm swings to pretax profit of GBP13.9 million from loss of GBP20.2 million in 2020. Firm boosted by GBP5.0 million gain on change in fair value of investment properties, versus hit of GBP27.9 million the year before. EPRA net tangible assets stand at 58.8p at end of 2021, up from 55.2p at end of 2020. Dividend for year is 3.0625p, up 2.1%.

----------

Online Blockchain PLC - Ongar, England-based blockchain research and development company - Revenue for six months to end of December GBP24,000, down from GBP56,000 a year before. Pretax loss widens to GBP468,000 from GBP76,000. Says ADVFN PLC is performing well, with revenue flat at GBP4.2 million in the period. "As you may have seen, I have stepped down as a director of ADVFN PLC which remains an important investment of Online Blockchain PLC. It is clear that subsequent to ongoing corporate activity around ADVFN, that ADVFN will experience an accelerate pace of change which we will work hard to ensure is positive," says Chief Executive Clement Chambers. Chambers co-founded ADVFN alongside Chair Michael Hodges.

----------

Schroder British Opportunities Trust PLC - provides fresh equity capital to growing small to mid-sized British businesses - Net asset value per share 112.72p at end of 2021, up from 108.44p at June 30. Says this growth of 3.9% in the period was marginally behind its declared total return target of 10% per annum, although it remains ahead of this target in the period since IPO in December 2020 with an annualised return of 13.7%.

----------

Harworth Group PLC - Rotherham, South Yorkshire-based land regenerator - EPRA net disposal value per share 197.6p at end of 2021, up from 160.0p a year before. Total return for year 24.6%, which firm notes is its highest figure to date, after return of 3.0% in 2020. Total dividend for year 1.212p, representing 10% underlying growth from 2020. In 2020 firm paid out 1.8p as dividend, but notes that the 2020 final dividend was increased to reflect the cancelled final 2019 dividend. "Our core sectors continue to perform well, but are not immune to wider macroeconomic pressures. Our focus now is on the execution of the strategy, ensuring that, as we work through our plans, the team has the skills and resources to deliver consistently and successfully, sustainably growing the business and delivering returns through the cycle," says Chief Executive Lynda Shillaw.

----------

Pebble Group PLC - Manchester-based technology and services for promotional products industry - Revenue for 2021 rises to GBP115.1 million from GBP82.4 million in 2020, surpassing 2019's figure of GBP107.2 million. Pretax profit jumps to GBP9.3 million from GBP5.0 in 2020. "Facilisgroup and Brand Addition performed well in the year under review, both financially and in building their differentiation in the market," company says. Adds that new financial year has started well and in line with its expectations.

----------

BioPharma Credit PLC - life sciences debt investment trust - Net asset value per share at December 31 99.26 cents, down from 100.37 cents a year before. Pays dividend of 7.29 cents per share in period, ahead of its 7 cent target. "Despite turbulent market conditions our highly resilient business model continued to deliver revenue as expected being uncorrelated from equity market movements and, uniquely for a London listed investment company, derived principally from cash flows from approved life science products," says Pedro Gonzalez de Cosio, chief executive & co-founder of Pharmakon Advisors LP, the investment manager of BioPharma Credit.

----------

Diurnal Group PLC - Cardiff, Wales-based pharmaceutical company focused on hormonal diseases - Revenue for half-year to December 31 rises to GBP2.1 million from GBP1.2 million, but pretax loss widens to GBP9.2 million from GBP5.3 million. This is largely due to higher research & development expenditure. In early March, firm was "disappointed" to receive the Scottish Medicines Consortium decision not to recommend Efmody for automatic reimbursement in Scotland, which it warns will impact near-term revenue in the UK. "The company's initial assessment of the impact of the recent SMC decision is that, despite continued strong growth (expected to be in excess of 100% for the 12-month period ended 30 June 2022), near-term sales expectations for Efmody are unlikely to be met and that further funding will be required to reach profitability," it says.

----------

Fintel PLC - Huddersfield, England-based technology and support for retail financial services sector - Revenue for 2021 rises to GBP63.9 million from GBP61.0 million and pretax profit nearly doubles at GBP19.9 million from GBP10.2 million. Makes GBP4.3 million gain on sale of subsidiary and GBP3.5 million on sale of operations. "2022 has started positively. Trading has been strong and in line with the board's expectations. We continue to make rapid progress on our strategic delivery and are confident that the company is in a strong position for further growth," it says. Proposes final dividend of 2p per share, resulting in full-year dividend of 3p, up from 2.85p in 2020.

----------

IQGeo Group PLC - Cambridge-based geospatial productivity and collaboration software company focused on the telecoms and utility industries - Revenue for 2021 rises to GBP13.8 million from GBP9.2 million in 2020, and pretax loss narrows to GBP2.7 million from GBP4.4 million. Says GBP3.4 million of new annual recurring revenue added in the year, up from GBP1.4 million in 2020. "We are very pleased to report that we have come out ahead of our own expectations for the financial year and made real progress towards our aim of building a high recurring revenue software business," says Chief Executive Richard Petti. Expects adjusted earnings before interest, tax, depreciation and amortisation and cash flow break even during 2022. Adjusted Ebitda loss for 2021 was GBP800,000, narrowed from GBP2.5 million in 2020.

----------

Princess Private Equity Holding Ltd - invests in private equity and private debt investments - Net asset value stands at EUR15.26 per share at end of 2021, up 19% over the year. Princess paid a total dividend of EUR0.67 per share during the year, in line with previous guidance to distribute 5% of opening NAV for each financial year. For 2022, the company intends to maintain this 5% distribution level. Realisations amounted to EUR462.5 million in the year and investment activity totalled EUR342.4 million

----------

Alliance Pharma PLC - Chippenham, England-based distributor of consumer healthcare brands and prescription medicines - Revenue for 2021 grows to GBP163.2 million from GBP129.8 million in 2020, and pretax profit improves to GBP18.2 million from GBP13.0 million. Says strong overall revenue growth driven by Consumer Healthcare, which saw see-through revenue grow 31% to GBP121.8 million. Firm says 2022 has started well. Expects increased growth from Nizoral in 2022 and sales growth acceleration for Amberen. "Our clear focus on the core Consumer Healthcare business in addition to our well-established, scalable platform across EMEA, APAC and the US, should support significant organic growth this year and beyond," company says.

----------

By Lucy Heming; lucyheming@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
21 Nov 2022 11:21

BioPharma Credit agrees loan agreement with subsidiary for Immunocore

(Alliance News) - BioPharma Credit PLC said on Monday it has entered into a definitive senior secured loan agreement with its fully-owned subsidiary BioPharma Credit Investments V Master LP for Immunocore Ltd.

Read more
20 Oct 2022 14:00

BioPharma makes investment in Insmed for disease therapy development

(Alliance News) - BioPharma Credit PLC on Thursday said it has made a USD140.0 million investment in US biopharmaceutical company Insmed Inc for the development of therapies to treat neutrophil-mediated inflammatory diseases and rare pulmonary disorders.

Read more
13 Oct 2022 12:26

IN BRIEF: BioPharma Credit pays special dividend; NAV increases

BioPharma Credit PLC - Winchester, England-based life sciences debt investment trust - Declares an interim dividend of USD0.0625 for its third quarter ended September 30. This comprises of a special dividend of USD0.0450 and an ordinary dividend of USD0.0175. Says it is on track to pay and continues to target a 7 cent base annual dividend.

Read more
6 Oct 2022 12:59

IN BRIEF: BioPharma Credit receives USD175 million from Pfizer deal

Biopharma Credit PLC - New York-based life sciences debt investment trust - Company's investment manager, Pharmakon Advisors, notes the announcement made by Pfizer Inc on Wednesday about acquisition of Global Blood Therapeutics for USD5.4 billion. BioPharma had USD132.5 million investment in Global Blood Therapeutics in a senior secured loan which has been prepaid following the acquisition. The senior secured loan was invested through three different tranches. In total the company received USD175.4 million, including USD42.9 million of accrued interest, paydown, prepayment and make-whole fees, realising an internal rate of return of 28%.

Read more
14 Sep 2022 10:42

BioPharma Credit net asset value and half-year profit both rise

(Alliance News) - BioPharma Credit PLC on Wednesday posted a slightly higher net asset value as profit shot up on the back of increased investment.

Read more
7 Sep 2022 15:53

UK earnings, trading statements calendar - next 7 days

Thursday 8 September 
Arecor Therapeutics PLCHalf Year Results
Cairn Homes PLCHalf Year Results
Chaarat Gold Holdings LtdHalf Year Results
Curtis Banks Group PLCHalf Year Results
Darktrace PLCFull Year Results
Destiny Pharma Holdings PLCHalf Year Results
Duke Royalty LtdFull Year Results
Emis Group PLCHalf Year Results
Energean PLCHalf Year Results
Funding Circle Holdings PLCHalf Year Results
Genus PLCFull Year Results
International Public Partnerships LtdHalf Year Results
Melrose Industries PLCHalf Year Results
Mpac Group PLCHalf Year Results
M Winkworth PLCHalf Year Results
Oakley Capital Investments LtdHalf Year Results
Open Orphan PLCHalf Year Results
Restaurant Group PLCHalf Year Results
Safestore Holdings PLCQ3 Results
Severfield PLCFull Year Results
Shield Therapeutics PLCHalf Year Results
SourceBio International PLCHalf Year Results
Spire Healthcare Group PLCHalf Year Results
Sylvania Platinum LtdFull Year Results
Vistry Group PLCHalf Year Results
Friday 9 September 
Computacenter PLCHalf Year Results
Creo Medical Group PLCHalf Year Results
Mid Wynd International Investment Trust PLCFull Year Results
Monday 12 September 
ABCAM PLCHalf Year Results
Arcontech Group PLCFull Year Results
Associated British Foods PLCFull Year Results
Greencoat Renewables PLCHalf Year Results
HgCapital Trust PLCHalf Year Results
Kape Technologies PLCHalf Year Results
Made Tech Group PLCFull Year Results
MP Evans Group PLCHalf Year Results
SigmaRoc PLCHalf Year Results
Tirupati Graphite PLCFull Year Results
Tuesday 13 September 
accesso Technology Group PLCHalf Year Results
Churchill China PLCHalf Year Results
Corero Network Security PLCHalf Year Results
Engage XR Holdings PLCHalf Year Results
Facilities by ADF PLCHalf Year Results
Fevertree Drinks PLCHalf Year Results
Futura Medical PLCHalf Year Results
Gateley Holdings PLCFull Year Results
Harworth Group PLCHalf Year Results
HeiQ PLCHalf Year Results
JTC PLCHalf Year Results
Mattioli Woods PLCFull Year Results
Ocado Group PLCTrading Statement
Oxford Nanopore Technologies PLCHalf Year Results
Petra Diamonds LtdFull Year Results
Property Franchise Group PLCHalf Year Results
RBG Holdings PLCHalf Year Results
Smart Metering Systems PLCHalf Year Results
Team17 Group PLCHalf Year Results
Trustpilot Group PLCHalf Year Results
VH Global Sustainable Energy Opportunities PLCHalf Year Results
Wednesday 14 September 
Anpario PLCHalf Year Results
Advanced Medical Solutions Group PLCHalf Year Results
BioPharma Credit PLCHalf Year Results
Blackbird PLCHalf Year Results
Central Asia Metals PLCHalf Year Results
Diurnal Group PLCHalf Year Results
Dunelm Group PLCFull Year Results
Epwin Group PLCHalf Year Results
Glenveagh Properties PLCHalf Year Results
ITM Power PLCFull Year Results
Niox Group PLCHalf Year Results
Pan African Resources PLCFull Year Results
Pharos Energy PLCHalf Year Results
Redrow PLCFull Year Results
Ricardo PLCFull Year Results
STM Group PLCHalf Year Results
Artisanal Spirits Co PLCHalf Year Results
Tullow Oil PLCHalf Year Results
  
Copyright 2022 Alliance News Limited. All Rights Reserved.

Read more
22 Aug 2022 19:00

IN BRIEF: BioPharma Credit says Epizyme investment repaid amid buyout

BioPharma Credit PLC - life sciences debt investment trust - Says had USD110 million investment in Epizyme Inc in form of senior secured loan. "The loan was made in four different tranches and each tranche had different prepayment economics," BioPharma adds. Ipsen on Friday completed acquisition of biopharmaceutical firm Epizyme. BioPharma says has received USD119 million, including USD9 million prepayment and make-whole fees. Realises internal rate of return of just over 15%.

Read more
9 Aug 2022 09:53

IN BRIEF: BioPharma Credit may benefit as Pfizer buys investee GBT

BioPharma Credit PLC - life sciences debt investment trust - Says it has USD132.5 million investment in Global Blood Therapeutics Inc, a company which has agreed to be acquired by Pfizer Inc. BioPharma investment is in form of senior secured loan. Loan will be prepaid when Pfizer buy of GBT closes. "The loan was invested in three different tranches with each tranche subject to different prepayment economics," BioPharma adds. Should prepayment occur before start of October, BioPharma will receive US38 million through paydown, prepayment and make-whole fees.

Read more
20 Jul 2022 13:51

IN BRIEF: BioPharma revises loan agreements with Akebia Therapeutics

BioPharma Credit PLC - Winchester, England-based life sciences debt investment trust - Says that together with BioPharma Credit Investments V it has entered into a second amendment and waiver with Akebia Therapeutics Inc. This amends and waives certain provisions of the USD100 million loan agreement dated November 11, 2019. As a result of this amendment Akebia has made a USD25 million prepayment, reducing the outstanding balance to USD75 million. Akebia will make payments on the remaining balance as originally agreed, starting in September. The loan balance is expected to be USD27 million by January 2024.

Read more
28 Jun 2022 20:17

IN BRIEF: BioPharma Credit says Epizyme investment to be prepaid

BioPharma Credit PLC - life sciences debt investment trust - Notes Monday's announcement from Ipsen regarding its agreement to acquire Epizyme Inc. BioPharma has a USD110 million investment in a senior secured loan in Epizyme, which it says would be prepaid upon closing of the acquisition. "The loan was made in four different tranches with each tranche having a different prepayment economics. Depending on the actual timing of the prepayment, the company would be expected to receive between USD3 million to USD7 million in prepayment and make-whole fees," company explains.

Read more
6 Jun 2022 15:58

UK shareholder meetings calendar - next 7 days

Tuesday 7 June  
Animalcare Group PLCAGM
Arix Bioscience PLCAGM
Centrica PLCAGM
Integrated Diagnostics Holdings PLCAGM
Kooth PLCAGM
Ondine Biomedical IncAGM
Osirium Technologies PLCAGM
SpaceandPeople PLCAGM
TruFin PLCAGM
Wednesday 8 June  
Ascent Resources PLCAGM
Cambridge Cognition Holdings PLCAGM
City Pub Group PLCAGM
DP Eurasia NVAGM
Gem Diamonds LtdAGM
Hiro Metaverse Acquisitions I SAAGM
Itaconix PLCAGM
M&G Credit Income Investment Trust PLCAGM
Nostrum Oil & Gas PLCAGM
Parity Group PLCAGM
Petards Group PLCAGM
Safestyle UK PLCAGM
Savannah Resources PLCAGM
Third Point Investors LtdAGM
Woodbois LtdAGM
Thursday 9 June 
4basebio PLCAGM
Northbridge Industrial Services PLCGM re name change to Crestchic
Funding Circle Holdings PLCAGM
Northbridge Industrial Services PLCAGM
Dignity PLCAGM
Corero Network Security PLCAGM
Kosmos Energy PLCAGM
Kistos PLCAGM
Tungsten Corp PLCGM re Kofax Offer
BioPharma Credit PLCAGM
Checkit PLCAGM
Panther Metals PLCAGM
Instem PLCAGM
Kore Potash PLCAGM
Rambler Metals & Mining PLCAGM
Xpediator PLCAGM
Round Hill Music Royalty Fund LtdAGM
REA Holdings PLCAGM
Invesco Perpetual UK Smaller Companies Investment Trust PLCAGM
BlackRock Smaller Companies Trust PLCAGM
Friday 10 June 
Chariot LtdAGM
MP Evans Group PLCAGM
THG PLCAGM
Ergomed PLCAGM
Ultra Electronics Holdings PLCAGM
XLMedia PLCAGM
Monday 13 June 
Angus Energy PLCGM re second tranche of subscription shares and warrants
Elixirr International PLCAGM
Ocean Outdoor LtdGM re takeover by Atairos Group Inc
Jupiter Emerging & Frontier Income Trust PLCGM re voluntary liquidation
Mirriad Advertising PLCAGM
Saga PLCAGM
Spectra Systems CorpAGM
VPC Speciality Lending Investments PLCAGM
  
Copyright 2022 Alliance News Limited. All Rights Reserved.

Read more
22 Apr 2022 06:57

IN BRIEF: Investment manager completes sale of BioPharma Credit shares

BioPharma Credit PLC - life sciences debt investment trust - Pablo Legorreta, co-founder of Pharmakon Advisors, the company's investment manager, completes sale of 55.0 million shares in BioPharma, a 4.0% stake. The disposal, run by JP Morgan Cazenove, was at USD0.97 per share, so worth USD53.4 million. Legorreta, who also is founder & chief executive officer of Royalty Pharma, retains 21.7 million shares, a 1.6% stake. BioPharma Credit receives no proceeds, as the sale is of existing shares.

Read more
20 Apr 2022 15:58

IN BRIEF: BioPharma Credit investment manager in USD56 million sale

BioPharma Credit PLC - life sciences debt investment trust - Pablo Legorreta, co-founder of Pharmakon Advisors, the company's investment manager, will sell 55.0 million shares in BioPharma, a 4.0% stake. The sale will be conducted immediately by JP Morgan Cazenove as an accelerated book building process to institutional investors. At the current market price, the sale would be worth about USD56 million. Legorreta, who also is founder & chief executive officer of Royalty Pharma, will retain 21.7 million shares, a 1.6% stake. BioPharma Credit will receive no proceeds, as the sale is of existing shares.

Read more
15 Mar 2022 15:52

UK earnings, trading statements calendar - next 7 days

Wednesday 16 March  
4imprint Group PLCFull Year Results
Advanced Medical Solutions Group PLCFull Year Results
Centamin PLCFull Year Results
Centaur Media PLCFull Year Results
CLS Holdings PLCFull Year Results
Computacenter PLCFull Year Results
Eagle Eye Solutions Group PLCHalf Year Results
Fevertree Drinks PLCFull Year Results
Gelion PLCHalf Year Results
Gym Group PLCFull Year Results
LSL Property Services PLCFull Year Results
PensionBee Group PLCFull Year Results
Pharos Energy PLCFull Year Results
Restaurant Group PLCFull Year Results
Restore PLCFull Year Results
RPS Group PLCFull Year Results
Science Group PLCFull Year Results
Thursday 17 March  
Ceres Power Holdings PLCFull Year Results
Cineworld Group PLCFull Year Results
Deliveroo PLCFull Year Results
Emis Group PLCFull Year Results
Empresaria Group PLCFull Year Results
FDM Group PLCFull Year Results
Gem Diamonds LtdFull Year Results
Harbour Energy PLCFull Year Results
Helios Towers PLCFull Year Results
Marshalls PLCFull Year Results
Mpac Group PLCFull Year Results
Ocado Group PLCQ1 Results
PensionBee Group PLCFull Year Results
Trainline PLCTrading Statement
TransGlobe Energy CorpFull Year Results
Tribal Group PLCFull Year Results
Wickes Group PLCFull Year Results
Friday 18 March  
ContourGlobal PLCFull Year Results
Essentra PLCFull Year Results
Eurocell PLCFull Year Results
Investec PLCTrading Statement
J D Wetherspoon PLCHalf Year Results
S4 Capital PLCFull Year Results
Monday 21 March 
Photo-Me International PLCFull Year Results
Spectral MD Holdings LtdFull Year Results
Sthree PLCTrading Statement
Tuesday 22 March 
Alliance Pharma PLCFull Year Results
BioPharma Credit PLCFull Year Results
Circassia Group PLCFull Year Results
Diaceutics PLCFull Year Results
Diurnal Group PLCFull Year Results
IQGeo Group PLCFull Year Results
Longboat Energy PLCFull Year Results
Luceco PLCFull Year Results
MaxCyte IncFull Year Results
MP Evans Group PLCFull Year Results
Oxford Nanopore Technologies PLCFull Year Results
Pebble Group PLCFull Year Results
Real Estate Investors PLCFull Year Results
Sabre Insurance Group PLCFull Year Results
ScS Group PLCHalf Year Results
Softcat PLCHalf Year Results
Staffline Group PLCFull Year Results
Trustpilot Group PLCFull Year Results
YouGov PLCHalf Year Results
Zotefoams PLCFull Year Results
  
Copyright 2022 Alliance News Limited. All Rights Reserved.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.